Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents

European Journal of Medicinal Chemistry

Volumn 66, Issue , 2013, Pages 324-334

  Torres, Enrique ^a   Moreno Viguri, Elsa ^a,b   Galiano, Silvia ^a   Devarapally, Goutham ^c   Crawford, Philip W ^c   Azqueta, Amaia ^a   Arbillaga, Leire ^a   Varela, Javier ^d   Birriel, Estefanía ^d   Di Maio, Rossanna ^d   Cerecetto, Hugo ^d   González, Mercedes ^d   Aldana, Ignacio ^a   Monge, Antonio ^a   Pérez Silanes, Silvia ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c SOUTHEAST MISSOURI STATE UNIVERSITY   (United States)

^d UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

Chagas disease; Cytotoxicity; Mutagenicity; Quinoxaline 1,4 di N oxide; Reduction potential; Trypanosoma cruzi

Indexed keywords

2 ETHOXYCARBONYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 2 ETHOXYCARBONYL 3,7 BIS(TRIFLUOROMETHYL)QUINOXALINE 1,4 DI N OXIDE; 2 ETHOXYCARBONYL 6,7 DIFLUORO 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 2 ETHOXYCARBONYL 6,7 DIMETHYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 2 ETHOXYCARBONYL 7 FLUORO 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 2 ETHOXYCARBONYL 7 METHOXY 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 2 ETHOXYCARBONYL 7 METHYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 2 METHOXYCARBONYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 2 METHOXYCARBONYL 3,7 BIS(TRIFLUOROMETHYL)QUINOXALINE 1,4 DI N OXIDE; 2 METHOXYCARBONYL 6,7 DIMETHYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 2 METHOXYCARBONYL 7 METHYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 6,7 DICHLORO 2 ETHOXYCARBONYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 6,7 DICHLORO 2 METHOXYCARBONYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 6,7 FLUORO 2 METHOXYCARBONYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 7 CHLORO 2 ETHOXYCARBONYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 7 CHLORO 2 METHOXYCARBONYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 7 FLUORO 2 METHOXYCARBONYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 7 METHOXY 2 METHOXYCARBONYL 3 TRIFLUOROMETHYLQUINOXA LINE 1,4 DI N OXIDE; ANTICHAGASIC AGENT; ANTIPARASITIC AGENT; NIFURTIMOX; OXIDE; QUINOXALINE 1,4 DI N OXIDE; QUINOXALINE DERIVATIVE; TRICHLOROETHYLENE; UNCLASSIFIED DRUG; 6,7 DIFLUORO 2 METHOXYCARBONYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; 7 METHOXY 2 METHOXYCARBONYL 3 TRIFLUOROMETHYLQUINOXALINE 1,4 DI N OXIDE; ANTIPROTOZOAL AGENT; QUINOXALINE 1,4 DI N OXIDE DERIVATIVE;

AMES TEST; ANTIPROTOZOAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CHAGAS DISEASE; CYCLIC POTENTIOMETRY; DRUG CYTOTOXICITY; ELECTROCHEMISTRY; ELECTRON; EPIMASTIGOTE; HUMAN; IC 50; IN VITRO STUDY; INFRARED SPECTROSCOPY; MAMMAL CELL; MICROWAVE THERAPY; MUTAGENICITY; NEGLECTED DISEASE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION TIME; SALMONELLA TYPHIMURIUM; THIN LAYER CHROMATOGRAPHY; TRYPANOSOMA CRUZI; BEIRUT REACTION; CHEMICAL REACTION; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ELECTROCHEMICAL ANALYSIS; REDUCTION;

EID: 84879496528     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.04.065     Document Type: Article

References (66)

1. A. Rassi Jr., A. Rassi, J.A. Marin-Neto, Chagas disease, Lancet 375 (9723) (2010) 1388-1402.
2. F.X. Lescure, G. Le Loup, H. Freilij, M. Develoux, L. Paris, L. Brutus, G. Pialoux, Chagas disease: changes in knowledge and management, The Lancet Infectious Diseases 10 (8) (2010) 556-570.
3. J.R. Coura, J. Borges-Pereira, Chagas disease: 100 years after its discovery. A systemic review, Acta Tropica 115 (1-2) (2010) 5-13.
4. Thirteenth Program Report, UNDP/World Bank/World Health Organization Program for Research and Training in Tropical Diseases, World Health Organization, Geneva, 2010.
5. www.paho.org/chagas.
6. G.A. Schmunis, Epidemiology of Chagas disease in non-endemic countries: the role of international migration, Memorias do Instituto Oswaldo Cruz 102 (Suppl. 1) (2007) 75-85. (Pubitemid 350146006)
7. G.A. Schmunis, Z.E. Yadon, Chagas disease: a Latin American health problem becoming a world health problem, Acta Tropica 115 (1-2) (2010) 14-21.
8. L.V. Kirchhoff, Epidemiology of American trypanosomiasis (Chagas disease), Advances in Parasitology 75 (2011) 1-18.
9. J.C. Dias, A.C. Silveira, C.J. Schofield, The impact of Chagas disease control in Latin America: a review, Memorias do Instituto Oswaldo Cruz 97 (5) (2002) 603-612. (Pubitemid 135746072)
10. J.A. Urbina, R. Docampo, Specific chemotherapy of Chagas disease: controversies and advances, Trends in Parasitology 19 (11) (2003) 495-501. (Pubitemid 37329658)
11. J.A. Urbina, Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches, Acta Tropica 115 (1-2) (2010) 55-68.
12. J.R. Coura, S.L. de Castro, A critical review on Chagas disease chemotherapy, Memorias do Instituto Oswaldo Cruz 97 (1) (2002) 3-24. (Pubitemid 135746197)
13. J.R. Coura, P.A. Vinas, Chagas disease: a new worldwide challenge, Nature 465 (7301) (2010) S6-S7.
14. A. Carta, P. Corona, M. Loriga, Quinoxaline 1,4-dioxide: a versatile scaffold endowed with manifold activities, Current Medicinal Chemistry 12 (19) (2005) 2259-2272. (Pubitemid 41179711)
15. M. González, H. Cerecetto, A. Monge, Quinoxaline 1,4-dioxide and phenazine 5,10-dioxide. Chemistry and biology, Topics in Heterocyclic Chemistry 11 (2007) 179-211.
16. B. Zarranz, A. Jaso, I. Aldana, A. Monge, Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl- quinoxaline 1,4-di-N-oxide derivatives, Bioorganic & Medicinal Chemistry 12 (13) (2004) 3711-3721. (Pubitemid 38746875)
17. B. Solano, V. Junnotula, A. Marin, R. Villar, A. Burguete, E. Vicente, S. Perez-Silanes, I. Aldana, A. Monge, S. Dutta, U. Sarkar, K.S. Gates, Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues, Journal of Medicinal Chemistry 50 (22) (2007) 5485-5492. (Pubitemid 350057858)
18. E. Moreno, S. Ancizu, S. Perez-Silanes, E. Torres, I. Aldana, A. Monge, Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives, European Journal of Medicinal Chemistry 45 (10) (2010) 4418-4426.
19. S. Ancizu, E. Moreno, E. Torres, A. Burguete, S. Perez-Silanes, D. Benitez, R. Villar, B. Solano, A. Marin, I. Aldana, H. Cerecetto, M. Gonzalez, A. Monge, Heterocyclic-2-carboxylic acid (3-cyano-1,4-di-N-oxidequinoxalin-2-yl) amide derivatives as hits for the development of neglected disease drugs, Molecules 14 (6) (2009) 2256-2272.
20. G. Aguirre, H. Cerecetto, R. Di Maio, M. Gonzalez, M.E. Alfaro, A. Jaso, B. Zarranz, M.A. Ortega, I. Aldana, A. Monge-Vega, Quinoxaline N,N′-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships, Bioorganic & Medicinal Chemistry Letters 14 (14) (2004) 3835-3839. (Pubitemid 38760089)
21. E. Vicente, P.R. Duchowicz, D. Benitez, E.A. Castro, H. Cerecetto, M. Gonzalez, A. Monge, Anti-T. cruzi activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides, Bioorganic & Medicinal Chemistry Letters 20 (16) (2010) 4831-4835.
22. E. Torres, E. Moreno, S. Ancizu, C. Barea, S. Galiano, I. Aldana, A. Monge, S. Perez-Silanes, New 1,4-di-N-oxide-quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-mycobacterium tuberculosis agents, Bioorganic & Medicinal Chemistry Letters 21 (12) (2011) 3699-3703.
23. A. Burguete, E. Pontiki, D. Hadjipavlou-Litina, S. Ancizu, R. Villar, B. Solano, E. Moreno, E. Torres, S. Perez, I. Aldana, A. Monge, Synthesis and biological evaluation of new quinoxaline derivatives as antioxidant and antiinflammatory agents, Chemical Biology & Drug Design 77 (4) (2011) 255-267.
24. C. Barea, A. Pabon, D. Castillo, M. Zimic, M. Quiliano, S. Galiano, S. Perez-Silanes, A. Monge, E. Deharo, I. Aldana, New salicylamide and sulfonamide derivatives of quinoxaline 1,4-di-N-oxide with antileishmanial and antimalarial activities, Bioorganic & Medicinal Chemistry Letters 21 (15) (2011) 4498-4502.
25. C. Barea, A. Pabon, S. Galiano, S. Perez-Silanes, G. Gonzalez, C. Deyssard, A. Monge, E. Deharo, I. Aldana, Antiplasmodial and leishmanicidal activities of 2-cyano-3-(4-phenylpiperazine-1-carboxamido) quinoxaline 1,4-dioxide derivatives, Molecules 17 (8) (2012) 9451-9461.
26. E. Vicente, S. Charnaud, E. Bongard, R. Villar, A. Burguete, B. Solano, S. Ancizu, S. Perez-Silanes, I. Aldana, L. Vivas, A. Monge, Synthesis and antiplasmodial activity of 3-furyl and 3-thienylquinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives, Molecules 13 (1) (2008) 69-77.
27. D. Benitez, M. Cabrera, P. Hernandez, L. Boiani, M.L. Lavaggi, R. Di Maio, G. Yaluff, E. Serna, S. Torres, M.E. Ferreira, N. Vera de Bilbao, E. Torres, S. Perez-Silanes, B. Solano, E. Moreno, I. Aldana, A. Lopez de Cerain, H. Cerecetto, M. Gonzalez, A. Monge, 3-Trifluoromethylquinoxaline N,N′-dioxides as antitrypanosomatid agents. Identification of optimal anti- T. cruzi agents and mechanism of action studies, Journal of Medicinal Chemistry 54 (10) (2011) 3624-3636.
28. F. Mavandadi, A. Pilotti, The impact of microwave-assisted organic synthesis in drug discovery, Drug Discovery Today 11 (3-4) (2006) 165-174. (Pubitemid 43375968)
29. M. Larhed, A. Hallberg, Microwave-assisted high-speed chemistry: a new technique in drug discovery, Drug Discovery Today 6 (8) (2001) 406-416. (Pubitemid 32328295)
30. C.O. Kappe, D. Dallinger, The impact of microwave synthesis on drug discovery, Nature Reviews Drug Discovery 5 (1) (2006) 51-63.
31. B. Wathey, J. Tierney, P. Lidstrom, J. Westman, The impact of microwave-assisted organic chemistry on drug discovery, Drug Discovery Today 7 (6) (2002) 373-380. (Pubitemid 34228904)
32. S. Ancizu, E. Moreno, B. Solano, R. Villar, A. Burguete, E. Torres, S. Perez-Silanes, I. Aldana, A. Monge, New 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives as anti-mycobacterium tuberculosis agents, Bioorganic & Medicinal Chemistry 18 (7) (2010) 2713-2719.
33. L. Boiani, G. Aguirre, M. Gonzalez, H. Cerecetto, A. Chidichimo, J.J. Cazzulo, M. Bertinaria, S. Guglielmo, Furoxan-, alkylnitrate-derivatives and related compounds as anti-trypanosomatid agents: mechanism of action studies, Bioorganic & Medicinal Chemistry 16 (17) (2008) 7900-7907.
34. M. Boiani, L. Piacenza, P. Hernandez, L. Boiani, H. Cerecetto, M. Gonzalez, A. Denicola, Mode of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is oxidative stress involved? Biochemical Pharmacology 79 (12) (2010) 1736-1745.
35. B.N. Ames, J. McCann, E. Yamasaki, Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test, Mutation Research 31 (6) (1975) 347-364.
36. M.A. Ortega, Y. Sainz, M.E. Montoya, A. Jaso, B. Zarranz, I. Aldana, A. Monge, Anti-Mycobacterium tuberculosis agents derived from quinoxaline-2- carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide, Arzneimittel- Forschung 52 (2) (2002) 113-119. (Pubitemid 34145330)
37. J.F. Faucher, T. Baltz, K.G. Petry, Detection of an "epimastigote- like" intracellular stage of Tripanosma cruzi, Parasitology Research 81 (1995) 441-443.
38. M. Almeida-de Faría, E. Freymuller, W. Colli, M.J. Alves, Trypanosoma cruzi: characterization of an intracellular epimastigote-like form, Experimental Parasitology 92 (1999) 263-274. (Pubitemid 29372448)
39. K.M. Tyler, D.M. Engman, The life cycle of Trypanosoma cruzi revisited, International Journal of Parasitology 31 (2001) 472-481. (Pubitemid 32382045)
40. D. Bonnet-Delpon, Fluorine, an essential element for medicinal chemistry, Annales Pharmaceutiques Francaises 66 (1) (2008) 56-59.
41. S. Purser, P.R. Moore, S. Swallow, V. Gouverneur, Fluorine in medicinal chemistry, Chemical Society Reviews 37 (2) (2008) 320-330.
42. P. Shah, A.D. Westwell, The role of fluorine in medicinal chemistry, Journal of Enzyme Inhibition and Medicinal Chemistry 22 (5) (2007) 527-540.
43. W. Porcal, P. Hernandez, G. Aguirre, L. Boiani, M. Boiani, A. Merlino, A. Ferreira, R. Di Maio, A. Castro, M. Gonzalez, H. Cerecetto, Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships, Bioorganic & Medicinal Chemistry 15 (7) (2007) 2768-2781. (Pubitemid 46367695)
44. P.H. Rieger, in: Electrochemistry, Chapman and Hall, New York, 1994.
45. A.J. Bard, L.R. Faulkner, Electrochemical Methods: Fundamentals and Applications, second ed., Wiley, New York, 2001.
46. M.D. Ryan, R.G. Scamehorn, P. Kovacic, Charge transfer in the mechanism of drug action involving quinoxaline di-N-oxides, Journal of Pharmaceutical Sciences 74 (4) (1985) 492-495. (Pubitemid 15112949)
47. P.W. Crawford, R.G. Scamehorn, U. Hollstein, M.D. Ryan, P. Kovacic, Cyclic voltammetry of phenazines and quinoxalines including mono- and di-N-oxides. Relation to structure and antimicrobial activity, Chemico-Biological Interactions 60 (1) (1986) 67-84. (Pubitemid 17201294)
48. J.R. Ames, M.A. Houghtaling, D.L. Terrian, Cyclic voltammetry of some quinoxaline di-N-oxides and quinoxalines in dimethylformamide, Electrochimica Acta 37 (8) (1992) 1433-1436.
49. H. Miyazaki, Y. Matsuhisa, T. Kubota, Cyclic voltammetry of aromatic amine N-oxides in nonaqueous solvents and the stability of the free radicals produced, Bulletin of the Chemical Society of Japan 54 (1981) 3850.
50. E. Moreno, S. Pérez-Silanes, S. Gouravaram, A. Macharam, S. Ancizu, E. Torres, I. Aldana, A. Monge, P.W. Crawford, 1,4-Di-N-oxide quinoxaline-2-carboxamide: cyclic voltammetry and relationship between electrochemical behavior, structure and anti-tuberculosis activity, Electrochimica Acta 56 (9) (2011) 3270-3275.
51. S. Pérez-Silanes, G. Devarapally, E. Torres, E. Moreno, I. Aldana, A. Monge, P.W. Crawford, Cyclic voltammetric study of some anti-Chagas active quinoxaline 1,4-di-N-oxide-2-ketone derivatives, Helvetica Chimica Acta 96 (2013) 217-227.
52. K.R. Barqawi, M.A. Atfah, A cyclic voltammetric study of some quinoxaline di-N-oxides and quinoxalines in acetonitrile: substituent effect on the cathodic reduction, Electrochimica Acta 32 (4) (1987) 597-599.
53. P. Zuman, Substituent Effects in Organic Polarography. New York (1967).
54. G. Aguirre, H. Cerecetto, R. Di Maio, M. Gonzalez, W. Porcal, G. Seoane, M.A. Ortega, I. Aldana, A. Monge, A. Denicola, Benzo[1,2-c ]1,2,5-oxadiazole N-oxide derivatives as potential antitrypanosomal drugs. Structure-activity relationships. Part II, Archiv der Pharmazie 335 (1) (2002) 15-21.
55. G. Aguirre, M. Boiani, H. Cerecetto, A. Gerpe, M. Gonzalez, Y.F. Sainz, A. Denicola, C.O. De Ocariz, J.J. Nogal, D. Montero, J.A. Escario, Novel antiprotozoal products: imidazole and benzimidazole N-oxide derivatives and related compounds, Archiv der Pharmazie 337 (5) (2004) 259-270. (Pubitemid 39237383)
56. G. Aguirre, L. Boiani, M. Boiani, H. Cerecetto, R. Di Maio, M. Gonzalez, W. Porcal, A. Denicola, O.E. Piro, E.E. Castellano, C.M. Sant'Anna, E.J. Barreiro, New potent 5-substituted benzofuroxans as inhibitors of Trypanosoma cruzi growth: quantitative structure-activity relationship studies, Bioorganic & Medicinal Chemistry 13 (23) (2005) 6336-6346. (Pubitemid 41539297)
57. M.C. Caterina, I.A. Perillo, L. Boiani, H. Pezaroglo, H. Cerecetto, M. Gonzalez, A. Salerno, Imidazolidines as new anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships, Bioorganic & Medicinal Chemistry 16 (5) (2008) 2226-2234. (Pubitemid 351380953)
58. V.J. Aran, C. Ochoa, L. Boiani, P. Buccino, H. Cerecetto, A. Gerpe, M. Gonzalez, D. Montero, J.J. Nogal, A. Gomez-Barrio, A. Azqueta, A. Lopez de Cerain, O.E. Piro, E.E. Castellano, Synthesis and biological properties of new 5-nitroindazole derivatives, Bioorganic & Medicinal Chemistry 13 (9) (2005) 3197-3207.
59. A. Gerpe, G. Alvarez, D. Benitez, L. Boiani, M. Quiroga, P. Hernandez, M. Sortino, S. Zacchino, M. Gonzalez, H. Cerecetto, 5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene, Bioorganic & Medicinal Chemistry 17 (21) (2009) 7500-7509.
60. D.M. Maron, B.N. Ames, Revised methods for the Salmonella mutagenicity test, Mutation Research 113 (3-4) (1983) 173-215. (Pubitemid 13120319)
61. K. Mortelmans, E. Zeiger, The Ames Salmonella/microsome mutagenicity assay, Mutation Research 455 (1-2) (2000) 29-60.
62. M. Cabrera, M.L. Lavaggi, P. Hernandez, A. Merlino, A. Gerpe, W. Porcal, M. Boiani, A. Ferreira, A. Monge, A.L. de Cerain, M. Gonzalez, H. Cerecetto, Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction, Toxicology Letters 190 (2) (2009) 140-149.
63. F.P. Guengerich, Cytochrome P450s and other enzymes in drug metabolism and toxicity, The AAPS Journal 8 (1) (2006) E101-E111.
64. K.C. Chu, K.M. Patel, A.H. Lin, R.E. Tarone, M.S. Linhart, V.C. Dunkel, Evaluating statistical analyses and reproducibility of microbial mutagenicity assays, Mutation Research 85 (3) (1981) 119-132. (Pubitemid 11099464)
65. G. Gritzner, J. Kuta, Recommendations on reporting electrode potentials in nonaqueous solvents, Pure Applied Chemistry 56 (4) (1984) 461-466. (Pubitemid 14565316)
66. M.P. Strier, J.C. Cavagnol, The polarography of quinoxaline II. 6-Substituted derivatives, Journal of American Chemical Society 80 (1958) 1565-1568.